Asia-Pacific journal of clinical oncology最新文献

{"title":"Disparities in the Burden of Prostate Cancer and Its Trends in the Western Pacific Region, 1990-2021.","authors":"Lei Wu, Shijia Yang, Guohong Zhu, Yao Liu, Zhaoyu Zhang, Yan Han, Wei Dai, Jian Zou, Minghui Peng, Sunfang Jiang, Xiaopan Li","doi":"10.1111/ajco.70173","DOIUrl":"https://doi.org/10.1111/ajco.70173","url":null,"abstract":"<p><strong>Objective: </strong>We assessed long-term and recent trends, age and geographic disparities, and future prostate cancer (PC) burden in China, the Western Pacific Region (WPR), individual WPR locations, and globally from 1990 to 2021, with projections through 2035.</p><p><strong>Methods: </strong>We analyzed Global Burden of Disease Study 2021 estimates of incidence, mortality, prevalence, years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life years (DALYs) for China, WPR locations, sociodemographic index strata, and globally. Absolute numbers and age-standardized rates were examined separately. Joinpoint regression estimated average annual percent changes (AAPCs) for 1990-2021 and 2012-2021. Bayesian age-period-cohort models projected incidence and deaths for 2022-2035; projected YLLs and YLDs were combined to estimate DALYs.</p><p><strong>Results: </strong>In 2021, the WPR had an estimated 192,632 incident cases (95% UI, 159,855-227,328) and 69,365 deaths (95% UI, 56,577-83,449). During 1990-2021, age-standardized incidence and prevalence increased (AAPC, 1.64% and 2.40%), whereas mortality and the age-standardized DALY rate (ASDLR) were stable (0.00% and 0.02%). ASDLR declined in high-SDI and high-middle-SDI locations but increased in lower SDI locations, and burden rose steeply with age. During 2012-2021, age-standardized incidence and mortality declined (AAPC, -0.28%; 95% CI, -0.56% to -0.06%; p = 0.014; and -0.58%; 95% CI, -0.76% to -0.40%; p < 0.001), but country-level trends were heterogeneous. From 2022 to 2035, posterior mean ASDLR increased modestly in China and the WPR and declined globally; projected mean absolute DALYs increased in all three settings, with widening uncertainty.</p><p><strong>Conclusion: </strong>Absolute PC burden increased substantially in the WPR, whereas age-standardized patterns varied across measures, periods, age groups, SDI strata, and countries. Recent regional declines did not indicate uniform improvement, and projected increases in absolute DALYs suggest continuing growth in service needs. Locally adapted prevention, risk-appropriate early detection, diagnosis, and treatment planning are required.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148900042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"METTL3 Promotes the Growth of Triple-Negative Breast Cancer Cells by Modulating Ferroptosis-Related Oxidative Stress via the ELF1/GPX4 Axis.","authors":"Jincheng Wang, Wei Wang, Junjie Hu, Guanghui Wang, Xiaodan Wang, Wenyu Cui, Xinlei Liu, Xiaohu Lv, Ruiguang Yang, Jianguang Jia","doi":"10.1111/ajco.70171","DOIUrl":"https://doi.org/10.1111/ajco.70171","url":null,"abstract":"<p><p>Triple-negative breast cancer (TNBC) is an aggressive malignancy with limited treatment options, highlighting the urgent need to identify novel therapeutic targets. The present study investigates the role of the RNA methyltransferase METTL3 in promoting TNBC progression by modulating a ferroptosis-related phenotype, an iron-dependent form of regulated cell death. Using TNBC cell lines (BT549 and MDA-MB-231), we demonstrated that METTL3 overexpression significantly enhanced cell proliferation, while its knockdown suppressed growth. Mechanistically, METTL3 was associated with decreased lipid peroxidation, reactive oxygen species (ROS), intracellular Fe² ⁺ levels, and the pro-ferroptotic protein ACSL4, alongside increased glutathione and the key ferroptosis inhibitor GPX4. Bioinformatic analysis, MeRIP-PCR, and actinomycin D chase assays indicated that METTL3 was associated with increased N⁶-methyladenosine (m6A) enrichment, expression, and persistence of ELF1 mRNA. Dual-luciferase reporter assay further suggested that ELF1 may be involved in GPX4 transcriptional regulation. Crucially, the pro-proliferative and ferroptosis-associated effects of METTL3 overexpression were partially attenuated upon ELF1 knockdown or treatment with the ferroptosis inducer erastin. In conclusion, our findings suggest a novel METTL3/ELF1/GPX4 axis through which METTL3 promotes TNBC growth by regulating oxidative stress and ferroptosis-related markers, providing a basis for further investigation of this pathway in the context of TNBC biology and therapeutic development.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148904979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comprehensive Genomic Profiling Timeliness Beyond Laboratory Turnaround Time: A Patient-Facing Pathway Analysis.","authors":"Shinya Kajiura, Naohiko Nakamura, Ryuji Hayashi","doi":"10.1111/ajco.70176","DOIUrl":"https://doi.org/10.1111/ajco.70176","url":null,"abstract":"<p><strong>Aim: </strong>We evaluated the timeliness of the patient-facing comprehensive genomic profiling (CGP) pathway by separating laboratory and post-laboratory intervals within an expert panel-mediated process, using direct disclosure of results to patients as the endpoint.</p><p><strong>Methods: </strong>This single-center retrospective study included adult CGP test episodes performed under government-funded cancer genomic medicine at a Japanese university hospital between October 2019 and November 2025. The primary outcome was patient-centered turnaround time (TAT), defined as the interval from informed consent to direct disclosure of the CGP result to the patient. Laboratory TAT and pathway intervals were summarized descriptively, and laboratory TAT was compared across assays.</p><p><strong>Results: </strong>Among 882 CGP test episodes, median laboratory TAT was 14 days (interquartile range [IQR], 12-16) among 871 evaluable episodes. Among 828 evaluable episodes, median patient-centered TAT was 41 days (IQR 35-45). The laboratory analysis retained observed long intervals, including a maximum of 72 days; no episode was excluded solely because laboratory TAT exceeded 56 days. These findings indicate that laboratory TAT was only one component of the longer consent-to-disclosure pathway.</p><p><strong>Conclusion: </strong>In this routine-care CGP pathway, patient-facing timeliness depended on the full process from consent to direct patient disclosure. Patient-centered TAT should be monitored alongside laboratory TAT as a care-delivery measure.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148886284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CDK4/6 Inhibitors in the Management of Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Advanced Breast Cancer in Indonesia: Challenges, Opportunities, and Recommendations.","authors":"Sonar Soni Panigoro, Samuel J Haryono, Prihantono Prihantono, Dedy Hermansyah, Sumadi Lukman Anwar, Yohana Azhar, Febriyanto Kurniawan, Putu Anda Tusta Adiputra, Kristanto Yuli Yarso, Asdi Wihandono","doi":"10.1111/ajco.70168","DOIUrl":"https://doi.org/10.1111/ajco.70168","url":null,"abstract":"<p><p>Breast cancer (BC) is the most prevalent cancer affecting women globally, with Asia accounting for nearly half of all cases. BC represents a major public health issue, particularly in Indonesia, where it is the leading cancer type among women. Indonesia faces high rates of late-stage diagnoses and poor survival outcomes, largely driven by socioeconomic disparities, limitations in healthcare infrastructure, and delays in detection; challenges also encountered across comparable resource-constrained settings. Hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) remains challenging to manage due to the lack of curative treatment options. Current therapeutic strategies focus on prolonging survival and enhancing quality of life. In this context, cyclin-dependent kinase (CDK)4/6 inhibitors have emerged as a major advancement, significantly improving progression-free and overall survival in selected settings when used in combination with endocrine therapy (ET). The CDK4/6 inhibitors palbociclib, ribociclib, and abemaciclib have shown notable efficacy in Asian populations, despite a higher incidence of hematological toxicities. However, access to these therapies remains limited in Indonesia because they have not yet been incorporated into national treatment guidelines. This review underscores the critical role of CDK4/6 inhibitors in the treatment of HR+/HER2- ABC, with a particular focus on Indonesian patients. It supports consideration of these agents for inclusion in national clinical guidelines to enhance patient outcomes. Evidence-informed recommendations endorse their use in patients with ET-sensitive tumors and as a potential alternative to chemotherapy in selected aggressive cases involving visceral disease without immediately life-threatening organ dysfunction. Addressing the barriers to early diagnosis and expanding access to advanced therapies is crucial for improving BC management in Indonesia and comparable settings.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148873022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing Homologous Recombination Repair Mutation Testing in Prostate Cancer in Australia: Shifting the Focus to Hormone Sensitive Prostate Cancer.","authors":"Arun A Azad, Declan G Murphy, Edmond M Kwan, Anthony M Joshua","doi":"10.1111/ajco.70169","DOIUrl":"https://doi.org/10.1111/ajco.70169","url":null,"abstract":"<p><p>Homologous recombination repair (HRR) gene alterations are key drivers of disease in prostate cancer. This has led to great interest in HRR targeted therapies, particularly polyadenosine diphosphate-ribose inhibitors (PARPi), in the treatment of metastatic castrate resistant prostate cancer (mCRPC). HRR alterations are typically early events in prostate cancer tumorigenesis. As a result, clinical trials are investigating the efficacy of PARPi therapy in metastatic hormone sensitive prostate cancer (mHSPC). Recently, based on positive results from the phase III AMPLITUDE trial, niraparib was approved in the United States for the treatment of patients with BRCA2-mutated mHSPC. Positive results have also recently been obtained from the phase III TALAPRO-3 trial; talazoparib added to enzalutamide led to significantly better imaging-based progression-free survival than placebo plus enzalutamide among patients with mHSPC harboring HRR alterations. Furthermore, international guidelines now recommend HRR mutation testing for patients with mHSPC. However, in Australia there is currently no reimbursement for HRR mutation testing in the mHSPC setting. Here, we review the current knowledge of the clinical relevance of HRR alterations and highlight the benefits of genomic profiling of hormone-sensitive disease prior to the development of castrate resistant disease.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148839134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Prior Immune Checkpoint Inhibitor Treatment on the Efficacy of Weekly Paclitaxel and Cetuximab in Recurrent or Metastatic Head and Neck Cancer.","authors":"Shohei Tsutsumi, Shunsuke Miyamoto, Kaho Momiyama, Kohei Hagiwara, Taku Yamashita","doi":"10.1111/ajco.70163","DOIUrl":"https://doi.org/10.1111/ajco.70163","url":null,"abstract":"<p><strong>Aim: </strong>The optimal treatment sequence involving immune checkpoint inhibitors (ICIs) and chemotherapy for recurrent or metastatic head and neck cancer remains unclear. This study aimed to evaluate the efficacy of weekly paclitaxel and cetuximab (PTX + Cmab) following prior ICI treatment.</p><p><strong>Methods: </strong>We retrospectively analyzed 52 patients with unresectable recurrent or metastatic head and neck cancer who received PTX + Cmab. Patients were divided into two groups according to prior ICI treatment status. Treatment outcomes, including overall response rate (ORR), progression-free survival (PFS), and overall survival (OS), were compared.</p><p><strong>Results: </strong>The ORR was 42.2%. Patients with prior ICI treatment showed a significantly higher ORR compared to those without prior ICI treatment (61.5% vs. 15.8%, p = 0.003). PFS was significantly longer in patients with prior ICI treatment (median, 5.4 vs. 4.4 months, p = 0.04). OS did not differ significantly between the groups (median, 15.1 vs. 11.0 months).</p><p><strong>Conclusion: </strong>PTX + Cmab was associated with a higher response rate and longer PFS in patients with prior ICI treatment. These findings suggest a clinical association between prior ICI treatment and improved response to subsequent PTX + Cmab.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148808244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Immunotherapy Prescribing Restrictions on Time to Systemic Therapy and Outcomes in Metastatic Clear Cell Renal Carcinoma in Australia.","authors":"Evon Jude, Elizabeth Liow, Jeremy Shapiro, Arun A Azad, Megan Crumbaker, Ganes Pranavan, Christopher Hocking, Felicia Roncolato, Annabel Smith, Shirley Wong, Angelyn Anton, Julie Johns, Peter Gibbs, Ben Tran, Andrew Weickhardt","doi":"10.1111/ajco.70164","DOIUrl":"https://doi.org/10.1111/ajco.70164","url":null,"abstract":"<p><strong>Introduction: </strong>Combination immunotherapy (Ipi/Nivo) was approved in Australia in 2019 for metastatic clear cell kidney cancer (mccRCC) patients with International Metastatic Database Consortium (IMDC) intermediate and poor-risk. Although selected patients can safely delay treatment due to indolent disease, delaying treatment beyond 1 year in patients without other IMDC risk factors classifies them as favorable risk and prevents access to Ipi/Nivo. This study investigated the impact of Ipi/Nivo approval on timing of treatment initiation and outcomes.</p><p><strong>Methods: </strong>Multicenter retrospective cohort study analyzing real-world data from the Kidney canceR Australian registry and Biobank (KRAB) was used to identify patients > 18 years with mccRCC who received systemic therapy. Patient demographics, time to systemic therapy (TTST) from diagnosis of metastatic disease, and outcomes were compared for patients diagnosed with metastatic disease before and from January 2019.</p><p><strong>Results: </strong>A total of 494 patients met study criteria. The 256 patients diagnosed from 2019 had a significant decrease in both mean TTST (3.9 months from 15.3 months) and proportion with TTST ≥ 1 year (8.2% from 27.7%). More patients met criteria for intermediate and poor-risk disease from 2019 (61% from 49%). Of the 242 patients with de novo metastatic disease, the proportion with TTST ≥ 1 year decreased from 2019 (5.2% from 16.7%). Despite this, there was no significant difference in overall survival before and from 2019.</p><p><strong>Conclusion: </strong>Prescribing restrictions for Ipi/Nivo in Australia were associated with a substantial change in prescribing practice for patients with mccRCC, without any change in survival outcomes.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148787420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Healthcare Provider Perspectives on Barriers to Fertility Preservation in Oncology Care in Iraq: A Qualitative Study.","authors":"Abdulrahman Mohammed Agha, Mohammed Ibrahim Aladul","doi":"10.1111/ajco.70166","DOIUrl":"https://doi.org/10.1111/ajco.70166","url":null,"abstract":"<p><strong>Aim: </strong>To investigate the understanding, approach, and experience of fertility preservation counseling among oncology healthcare providers in Iraq in treating reproductive age cancer patients.</p><p><strong>Methods: </strong>We have performed a qualitative study with semi-structured face-to-face interviews with 27 healthcare providers who had been engaged in cancer care, such as oncologists and clinical pharmacists. Interviews were conducted to examine the level of awareness on fertility preservation, the existing counseling practice, the referral pathways, cultural factors, and perceived barriers. Transcription of audio-recorded interviews was done verbatim followed by inductive thematic analysis.</p><p><strong>Results: </strong>The healthcare providers were mostly aware of the need to talk about fertility preservation prior to cancer therapy, particularly in younger patients. Still, practice was uneven. They identified seven themes, which included awareness and understanding of fertility preservation; attitudes and beliefs; current counseling and referral practices; communication and patient education; cultural, religious, and financial influences; role of pharmacists and multidisciplinary care; and barriers and needs for improvement. The discourse of fertility preservation tended to rely on the personal initiative of clinicians and not on systematic channels. The main obstacles were low local fertility care, urgency in treatments, cost, ineffective referral systems, and embarrassment to talk about reproduction in a conservative environment.</p><p><strong>Conclusion: </strong>Fertility preservation awareness is present in this setting, although the implementation is uneven. To make fertility preservation a component of standard cancer care, more practical referral pathways, culturally sensitive educational resources, more explicit team roles, and enhanced cooperation between oncology and fertility services are required.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148787414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Steven-Johnson Syndrome and Toxic Epidermal Necrolysis in a Patient Treated With Cabozantinib: A Case Report of a Fatal Adverse Reaction.","authors":"Alberto Zambudio-Munuera, Miguel Herráez-Marcos, Miguel Angel Arrabal-Polo, Francisco Gutiérrez-Tejero, Miguel Arrabal-Martín","doi":"10.1111/ajco.70170","DOIUrl":"https://doi.org/10.1111/ajco.70170","url":null,"abstract":"<p><p>Cabozantinib is a multikinase inhibitor with high efficacy in patients with metastatic renal cell carcinoma. We present the case of a 53-year-old patient undergoing second-line treatment for metastatic renal cell carcinoma who presented with extensive skin lesions consistent with Stevens-Johnson syndrome, confirmed by biopsy. He presented a torpid course, progressing to toxic epidermal necrolysis and subsequent death despite supportive measures and immunoglobulin treatment. Although cabozantinib can cause skin reactions, such torpid and aggressive reactions as those observed in this clinical case have not been reported.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148787438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From Measurement to Impact: Cancer Registries and the Illusion of Improvement.","authors":"Raymond Phang, Andrew McCombie, Nikolajs Zeps, Alexander Heriot, Frank Frizelle","doi":"10.1111/ajco.70160","DOIUrl":"https://doi.org/10.1111/ajco.70160","url":null,"abstract":"","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148787282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}